Table 1 Patient characteristics of the study population

Sex

1.000**

 Male

37 (74.0)

15 (75.0)

 Female

13 (26.0)

5 (25.0)

Age (years)^†

63.8 ± 9.4

68.0 ± 8.8

0.085^#

BMI (kg/m²)^†

27.2 ± 3.9

28.9 ± 5.4

0.202^#

Ki-67 value (%)*

2.0 (1.0–6.7)

3.0 (1.0–17.0)

0.388^¶

Primary tumour location

0.760**

 Pancreas

28 (59.6)

7 (35.0)

 Small bowel

16 (34.0)

3 (15.0)

 Rectum

1 (2.1)

0 (0)

 Stomach

1 (2.1)

1 (5.0)

 Unknown location

1 (2.1)

0 (0)

 No tumour

3 (6.4)

9 (45.0)

Primary tumour resection

1.000**

 Resected

4 (8.5)

1 (9.1)

 Not resected

43 (91.5)

10 (90.9)

WHO NETs grade

0.134**

 I

24 (52.1)

3 (27.3)

 II

23 (47.9)

5 (45.5)

 III

0 (0)

1 (9.1)

 Unknown

0 (0)

2 (18.2)

Tumour stage

0.353**

 I

5 (10.6)

0 (0)

 II

14 (29.8)

3 (27.3)

 III

10 (21.3)

3 (27.3)

 IV

2 (4.3)

2 (18.2)

 Unknown

16 (34.0)

3 (27.3)

Metastasis

0.181**

 Yes

32 (68.1)

5 (45.5)

 No

15 (31.9)

6 (54.5)

PET/CT

0.359**

 Initial

36 (72.0)

3 (15.0)

 Follow-up

14 (28.0)

17 (85.0)

PET/CT scanner

1.000**

 Philips

41 (82.0)

17 (85.0)

 Siemens

9 (18.0)

3 (15.0)

 Activity (MBq/kg)^†

1.4 ± 0.2

1.4 ± 0.3

0.291^#

 Peptide (ng/kg)^†

158 ± 66

156 ± 91

0.954^#

[¹⁷⁷Lu]Lu-DOTA-TATE therapy

1.000**

 Yes

0 (0)

0 (0)

 No

47 (100)

11 (100)

CYP3A4 inhibitors

NA

 Verapamil

NA

10

 Amiodarone

NA

7

 Clarithromycin

NA

2

 Ketoconazole

NA

1